Sinocare Inc. (300298.SZ) has a MoatMap StockRank of 51/100 based on Quality (56/100), Value (32/100), and Momentum (48/100) factor scores. The current signal is HOLD. Sinocare is a leading Chinese manufacturer of blood glucose monitoring systems. While it has a solid domestic market share, it is a medical device company rather than a CDMO, and faces intense domestic price competition.
Sinocare Inc. is China's largest manufacturer of blood glucose monitoring systems, specializing in biosensor technology for diabetes management and point-of-care testing (POCT). The company commands a dominant share of China's retail OTC blood glucose meter market and has expanded its global footprint through strategic acquisitions like Trividia Health. Its low-cost manufacturing scale, extensive pharmacy distribution network, and expanding multi-analyte testing portfolio form a highly defensive competitive moat.
| Price | $2.21 |
| Market Cap | $1.3B |
| P/E (TTM) | 68.09 |
| P/E (Forward) | 16.83 |
| Price/Book | 2.62 |
| Return on Equity | 1.2% |
| Return on Invested Capital | 3.0% |
| Debt/Equity | 23.40 |
| Gross Margin | 49.0% |
| Operating Margin | 10.2% |
| Revenue Growth | 19.0% |
| Dividend Yield | 1.5% |
| Free Cash Flow | $4M |
Sinocare Inc. operates in the Medical Devices industry, part of the Healthcare sector (China).